Talphera, Inc. (TLPH) company profile
Close on Nov 16, 2026Market cap $44.69MP/E –Yield –
About Talphera
Pharmaceutical Preparations, SIC 2834
The company is a specialty pharmaceutical business dedicated to developing and commercializing therapies for medically supervised healthcare settings. Its lead pipeline product is Niyad, a regional anticoagulant formulated with nafamostat for infusion into extracorporeal circuits during continuous renal replacement therapy. The enterprise is also investigating LTX-608, a direct intravenous nafamostat formulation targeting conditions such as disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and viral infections. Intended customers and end users include hospital intensive care units, dialysis centers, and specialized clinical care providers.
Clinical development operations focus on the United States, where the business conducts registrational trials across hospital intensive care units. The company utilizes external contract manufacturing partners to produce its active drug substances and finished development formulations. Additionally, the corporate text references prior international commercial use of its core compound in Japan and South Korea, as well as European manufacturing facilities used by a third-party partner. The provided text does not state the company's specific headquarters location.
Summary of the business section of Talphera's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Talphera, Inc.
- Founded
- 2005
- Headquarters
- San Mateo, CA
- Address
- 1850 Gateway Drive, Suite 175 94404
- Phone
- (650) 216-3500
- Website
- www.acelrx.com
- Employees
- 12, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BPM LLP, Walnut Creek, California
Stock & identifiers
- Ticker
- TLPH
- Former tickers
- ACRX until Jan 9, 2024
- Exchange
- Nasdaq
- IPO date
- Feb 11, 2011
- Shares outstanding
- 52M, Aug 6, 2026
- Public float
- $8.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Oct 26, 2022
- SEC CIK
- 1427925
- CUSIP
- 00444T209
- ISIN
- US00444T2096
- FIGI
- BBG0018YYFX7
- Share class FIGI
- BBG001TFZCK5
- LEI
- 549300U8W781S4RBUE66
- EIN
- 41-2193603
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Vincent J. Angotti | CHIEF EXECUTIVE OFFICER, Director | 790,767 |
| Shakil Aslam | Chief Medical Officer | 76,542 |
| Badri N. Dasu | Chief Engineering Officer | 71,440 |
| Raffi Asadorian | Chief Financial Officer | 85,879 |
| Jill Marie Broadfoot | Director | 13,647 |
| Joseph Todisco | Director | 11,497 |
| Marina Bozilenko | Director | 14,147 |
| Abhinav Jain | Director | 12,412 |
| Adrian Adams | Director | 22,709 |
| Mark A. Wan | Director | 140,112 |
| Stephen J. Hoffman | Director | 2,885,892 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.12M | $1.50M | $691.08K | $50 | – |
| FY2024 | $1.04M | $844.56K | $642.91K | $23 | – |
| FY2023 | $1.21M | $1.01M | $778.44K | $33 | – |
| FY2022 | $1.30M | $692.48K | $788.77K | $20 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Vincent J. Angotti Chief Executive Officer | $688.81K | $206.64K | $35.56K | $172.26K | $14.00K | $1.12M | +8% |
| Raffi Asadorian Chief Financial Officer | $520.94K | $145.86K | $8.75K | $37.76K | $14.00K | $727.31K | +2% |
| Shakil Aslam Chief Medical Officer | $473.20K | $121.14K | $8.75K | $37.76K | $14.00K | $654.84K | +24% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 11, 2011
- Offer price
- $5.00
- Securities offered
- 8,000,000
- Gross proceeds
- $40.00M
- Exchange
- Nasdaq
- First trading day
- Feb 11, 2011
- First-day close
- $4.55-9.0%
- Lock-up ends (est.)
- Aug 10, 2011
“The initial public offering price is $5.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 12 full-time employees, most of whom work out of our corporate offices in San Mateo, CA.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?